九典制药：Q3净利1.15亿元，同比下降30.59%

Core Viewpoint - Jiutian Pharmaceutical reported a decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - Q3 2025 revenue reached 756 million yuan, a year-on-year decrease of 3.03% [1] - Net profit attributable to shareholders was 115 million yuan, down 30.59% year-on-year [1] - Basic earnings per share for Q3 2025 stood at 0.23 yuan [1] Year-to-Date Performance - For the first three quarters of 2025, the company achieved a total revenue of 2.268 billion yuan, reflecting a year-on-year growth of 5.69% [1] - Net profit attributable to shareholders for the first three quarters was 406 million yuan, a decline of 9.64% compared to the previous year [1] - Basic earnings per share for the first three quarters was 0.82 yuan [1]